-- New Module Expands Molecular Testing Capabilities,
Increases Productivity and Flexibility for the Laboratory
--
MARLBOROUGH, Mass.,
June 18, 2018 /CNW/ -- Hologic,
Inc. (Nasdaq: HOLX) announced today that it has obtained approval
from Health Canada for its new Panther Fusion® system and Panther
Fusion assays for respiratory virus infections. The Fusion module
offers laboratories the ability to extend the testing capabilities
of the existing Panther system.
The Panther Fusion module is an in-lab upgrade to the Panther®
instrument. This addition adds the flexibility of PCR
(polymerase chain reaction) to the proven performance of TMA
(transcription-mediated amplification), which is used by the
Panther system. Offering labs multiple chemistries on a
single platform enables further consolidation of lab testing. The
Panther Fusion system retains all the key benefits of the Panther
platform, including fully automated sample-to-result automation,
multiple tests from a single sample, random access sample
processing, continuous loading, and STAT capabilities.
Additional benefits include a higher throughput of up to 335
Panther Fusion tests in eight hours, or up to 500 Fusion and
Aptima® tests. Flexibility is also improved with the addition of
open access functionality to run laboratory-developed tests and
protocols. This new capability allows laboratories to
concentrate on developing assays, while the Panther Fusion system
automates workflow and reduces overall hands-on time.
"We're delighted to receive approval from Health Canada for the
Panther Fusion system, the latest innovation from our Diagnostics
division. This system creates an integrated workflow that provides
our customers with enhanced flexibility and increased efficiency,"
said Tom West, president, Diagnostic
Solutions Division at Hologic. "Three new assays for flu and
respiratory infections also were approved, which extend the range
of diagnostics tests that laboratories can run on one Hologic
system. Hologic's flu and respiratory assays enable customers to
run only the targets requested for a patient, allowing for
personalized testing and helping control costs."
The Panther Fusion respiratory assays include the Panther Fusion
Flu A/B/RSV, Panther Fusion Paraflu, and Panther Fusion AdV/hMPV/RV
tests. These PCR-based assays offer a modular approach to
syndromic testing via the ability to run one, two or all three
assays from a single patient specimen depending on the needs of a
given patient.
The new PCR-based Panther Fusion assays, combined with the
Aptima TMA assays, make the Panther Fusion system the only
instrument to combine TMA, real-time TMA and real-time PCR with
full sample to result automation.
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company
primarily focused on improving women's health and well-being
through early detection and treatment. For more information
on Hologic, visit www.hologic.com.
Hologic, The Science of Sure, Aptima and Panther are registered
trademarks of Hologic, Inc. in the United
States and/or other countries.
Forward-Looking Statements
This news release may contain forward-looking information that
involves risks and uncertainties, including statements about the
use of Hologic products. There can be no assurance these products
will achieve the benefits described herein or that such benefits
will be replicated in any particular manner with respect to an
individual patient, as the actual effect of the use of the products
can only be determined on a case-by-case basis. In addition, there
can be no assurance that these products will be commercially
successful or achieve any expected level of sales. Hologic
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any such statements presented
herein to reflect any change in expectations or any change in
events, conditions or circumstances on which any such data or
statements are based.
This information is not intended as a product solicitation or
promotion where such activities are prohibited. For specific
information on what products are available for sale in a particular
country, please contact a local Hologic sales representative or
write to womenshealth@hologic.com.
Hologic Media Contact:
Jane
Mazur
508.263.8764 (direct)
585.355.5978 (mobile)
jane.mazur@hologic.com
Hologic Investor Contact:
Michael Watts
Vice President, Investor Relations and Corporate Communications
(858) 410-8588
michael.watts@hologic.com
SOURCE Hologic, Inc.